Related Experiment Video

Updated: Jun 9, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

628

Association of SGLT2 inhibitors with incident cancer

Yuta Suzuki1, Hidehiro Kaneko2, Akira Okada3

  • 1The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan; Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.

Diabetes & Metabolism
|October 25, 2024
PubMed
Abstract

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) may reduce cancer risk in diabetic patients. This study found SGLT2i use was associated with a lower incidence of cancer compared to DPP4 inhibitors.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Oncology

Background:

  • The association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cancer incidence is not well-established.
  • Diabetes mellitus is a known risk factor for various cancers.

Purpose of the Study:

  • To investigate the potential association between SGLT2 inhibitors and the risk of developing incident cancer in individuals with diabetes.
  • To compare cancer incidence between patients newly prescribed SGLT2 inhibitors versus dipeptidyl peptidase 4 inhibitors.

Main Methods:

  • A large-scale, nationwide epidemiological database was utilized for analysis.
  • Propensity score matching was employed to create comparable cohorts of SGLT2i and DPP4i users.
  • Cancer incidence was the primary outcome, with a mean follow-up of 2.0 years.

Main Results:

  • SGLT2 inhibitor use was associated with a significantly reduced risk of overall cancer incidence (HR 0.80, 95% CI 0.70-0.91).
  • A notable reduction in colorectal cancer risk was observed with SGLT2i administration (HR 0.71, 95% CI 0.50-0.998).
  • Findings were robust across multiple sensitivity analyses, including overlap weighting and inverse probability of treatment weighting.

Conclusions:

  • Real-world data suggest SGLT2 inhibitors may offer a protective effect against cancer development in patients with diabetes.
  • SGLT2 inhibitors demonstrated a potential advantage over DPP4 inhibitors in reducing cancer risk.
  • Further research is warranted to elucidate the mechanisms behind this observed association.
Keywords:
CancerDiabetesEpidemiologySGLT2i

More Related Videos

Detecting Anastasis In Vivo by CaspaseTracker Biosensor20:16

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Published on: February 1, 2018

9.2K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
193
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.1K